Damora Therapeutics, Inc
Financing
SEC filings to 2026-10-05 · every row opens its filingShares on issue
61.7M
on 2026-06-30, from 1.08M on 2024-03-31 10-Q ↗
Earlier counts are adjusted for the 1-for-25 reverse split; each bar's tip shows the count as filed.
a raise that quarter, at its price
Newest
No limit
S-3ASR of 2026-02-10. An automatic shelf: the form sets no dollar limit. 1 prospectus supplement filed under it since. S-3ASR ↗
$150.0M
TD Securities (USA), agreement of 2026-02-10. No at-the-market sales statement read from a 10-Q or 10-K. S-3ASR ↗
Warrants
The 10-Q filed 2026-08-10 is not read yet.
Cash
48.6 quarters
$540.5M on 2026-06-30 ÷ $11.1M a quarter of operating cash used, the average of four quarters. 10-Q ↗
| Date | What | Shares | Price | Gross | Filing |
|---|---|---|---|---|---|
| 2026-02-11 | Public offering | 14,473,685 | $19.00 | $275.0M | 424B5 ↗ |